度拉糖肽对老年 2 型糖尿病患者血糖控制和膝骨关节炎疼痛的双重影响。
Dual effects of dulaglutide on glycemic control and knee osteoarthritis pain in elderly patients with Type 2 diabetes.
机构信息
Department of Diabetes & Allergy-Asthma, Therapeutics Specialty Clinic, Kolkata, West Bengal, India.
Department of Diabetes & Endocrinology, Apollo Sugar Clinic Kolkata, West Bengal, India.
出版信息
Pain Manag. 2024;14(7):365-373. doi: 10.1080/17581869.2024.2402214. Epub 2024 Sep 20.
This study aims to evaluate the dual benefits of dulaglutide in improving glycemic control and reducing knee OA pain. Elderly T2DM patients diagnosed with bilateral knee OA on conventional OA treatment for at least 3 months were studied for their glycemic metrics, OA pain scores and NSAID consumption at baseline, 3 months and 6 months. Significant improvements in glycemic control were observed, HbA1c decreased from 8.7% to 6.5% over 6 months. Pain scores, NSAID, body weight and BMI showed substantial reductions over time. Positive correlation (r = 0.73, < 0.001) was found between glycemic control and pain reduction. Dulaglutide improves glycemic control, knee joint OA pain and weight management in elderly patients with T2DM.
本研究旨在评估度拉糖肽在改善血糖控制和减轻膝骨关节炎疼痛方面的双重益处。对接受常规骨关节炎治疗至少 3 个月的双侧膝骨关节炎的老年 2 型糖尿病患者进行研究，以评估其血糖指标、骨关节炎疼痛评分和 NSAID 消耗情况，分别在基线、3 个月和 6 个月时进行评估。结果显示，患者的血糖控制得到显著改善，HbA1c 在 6 个月内从 8.7%降至 6.5%。疼痛评分、NSAID、体重和 BMI 随时间呈显著下降趋势。血糖控制与疼痛减轻之间存在正相关关系（r = 0.73，<0.001）。度拉糖肽可改善老年 2 型糖尿病患者的血糖控制、膝关节骨关节炎疼痛和体重管理。
Zotero 插件